{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:47:55Z","timestamp":1792756075665,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Purpose<\/jats:italic> Anticancer agents are known to increase cancer-associated thrombosis (CAT) onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel plus ramucirumab combination therapy, and 11.9% in bevacizumab monotherapy. Because immune checkpoint inhibitors (ICIs) cause a sudden increase in T cell number, an association between administration of these drugs and increase in CAT incidence is likely. However, the extent to which ICI administration affects CAT incidence remains unclear. Further, risk factors for CAT incidence have not yet been identified. The present study investigated CAT incidence and associated risk factors in patients receiving ICI. <jats:italic>Methods<\/jats:italic> Patients administered nivolumab or pembrolizumab at Fujita Health University Hospital from April 2017 to March 2018 were enrolled. We collected retrospective data regarding age, sex, cancer type, BMI, medical history, laboratory data at treatment initiation, medications, and computed tomography (CT) interpretations from electronic medical records. <jats:italic>Results<\/jats:italic> We identified 122 eligible participants from 135 patients receiving nivolumab or pembrolizumab. Ten patients (8.2%) developed CAT. A history of venous thromboembolism (VTE) or arterial thromboembolism (ATE) was a risk factor for CAT incidence (odds ratio: 6.36, <jats:italic>P<\/jats:italic>\u2009=\u20090.039). A history of heart disease may be a risk factor for CAT incidence (odds ratio 6.56, <jats:italic>P<\/jats:italic>\u2009=\u20090.052). Significantly higher usage of antiplatelet and anticoagulant therapy was noted in patients who developed CAT (60%) than in those who did not (13.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). <jats:italic>Conclusion<\/jats:italic> High (8.2%) CAT incidence during ICI administration suggested that ICI is not associated with a lower blood clot risk than other anticancer agents investigated in previous studies. For patients with VTE, ATE, or heart disease history, it is crucial to consider the possibility of CAT even with antiplatelet therapy.<\/jats:p>","DOI":"10.1007\/s10637-019-00881-6","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T15:35:56Z","timestamp":1576510556000},"page":"1200-1206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"38","author":[{"given":"Yosuke","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9686-6903","authenticated-orcid":false,"given":"Takahiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seira","family":"Nishibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"881_CR1","doi-asserted-by":"crossref","unstructured":"AACR 103rd Annual Meeting 2012-Mar 31-Apr 4, 2012; Chicago, IL","DOI":"10.1158\/AACR.EDB-12-8466"},{"key":"881_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125:490\u2013493","journal-title":"Thromb Res"},{"key":"881_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S et al (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715\u2013722","journal-title":"JAMA"},{"key":"881_CR4","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB, Reiner AS, Kamel H et al (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70:926\u2013938","journal-title":"J Am Coll Cardiol"},{"key":"881_CR5","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","volume":"27","author":"AA Khorana","year":"2009","unstructured":"Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839\u20134847","journal-title":"J Clin Oncol"},{"key":"881_CR6","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","volume":"30","author":"S Seng","year":"2012","unstructured":"Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 30:4416\u201344126","journal-title":"J Clin Oncol"},{"key":"881_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339","journal-title":"Lancet"},{"key":"881_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased\u03b1fetoprotein concentrations (REACH-2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:282\u2013296","journal-title":"Lancet Oncol"},{"key":"881_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placeboplus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"key":"881_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after firstline therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"881_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IVnon-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665\u2013673","journal-title":"Lancet"},{"key":"881_CR12","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277\u20132285","journal-title":"JAMA"},{"key":"881_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824\u20131835","journal-title":"N Engl J Med"},{"key":"881_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867","journal-title":"N Engl J Med"},{"key":"881_CR15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric orgastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471","journal-title":"Lancet"},{"key":"881_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jjco\/hyz026","volume":"49","author":"Y Tomita","year":"2019","unstructured":"Tomita Y, Fukasawa S, Shinohara N et al (2019) Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the phase III CheckMate 025 study. Jpn J Clin Oncol 49:506\u2013514","journal-title":"Jpn J Clin Oncol"},{"key":"881_CR17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/cas.13241","volume":"108","author":"N Yamazaki","year":"2017","unstructured":"Yamazaki N, Kiyohara Y, Uhara H et al (2017) Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study. Cancer Sci 108:1223\u20131230","journal-title":"Cancer Sci"},{"key":"881_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/cas.13225","volume":"108","author":"T Hida","year":"2017","unstructured":"Hida T, Nishio M, Nogami N et al (2017) Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci 108:1000\u20131006","journal-title":"Cancer Sci"},{"key":"881_CR19","doi-asserted-by":"publisher","first-page":"e000108","DOI":"10.1136\/esmoopen-2016-000108","volume":"1","author":"M Nishio","year":"2017","unstructured":"Nishio M, Hida T, Atagi S et al (2017) Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open 1:e000108","journal-title":"ESMO Open"},{"key":"881_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/cas.13230","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Hatake K, Kinoshita T et al (2017) Multicenter phase II study of nivolumabin Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci 108:1007\u20131012","journal-title":"Cancer Sci"},{"key":"881_CR21","doi-asserted-by":"crossref","unstructured":"Varki (2007) A Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110:1723\u20131729","DOI":"10.1182\/blood-2006-10-053736"},{"key":"881_CR22","doi-asserted-by":"publisher","first-page":"e10772","DOI":"10.1097\/MD.0000000000010772","volume":"97","author":"K Kunimasa","year":"2018","unstructured":"Kunimasa K, Nishino K, Kimura M et al (2018) Pembrolizumab-induced acute thrombosis: a case report. Medicine (Baltimore) 97:e10772","journal-title":"Medicine (Baltimore)"},{"key":"881_CR23","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Balko JM, Compton ML et al (2018) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755","journal-title":"N Engl J Med"},{"key":"881_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728","journal-title":"JAMA Oncol"},{"key":"881_CR25","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.115.017563","volume":"133","author":"SK Vasan","year":"2016","unstructured":"Vasan SK, Rostgaard K, Majeed A et al (2016) ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. Circulation 133:1449\u20131457","journal-title":"Circulation"},{"key":"881_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4103\/1947-2714.143278","volume":"6","author":"S Pulivarthi","year":"2014","unstructured":"Pulivarthi S, Gurram MK (2014) Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. N Am J Med Sci 6:491\u2013499","journal-title":"N Am J Med Sci"},{"key":"881_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2013-04-460147","volume":"122","author":"I Pabinger","year":"2013","unstructured":"Pabinger I, Thaler J, Ay C (2013) Biomarkers for prediction of venous thromboembolism in cancer. Blood 122:2011\u20132018","journal-title":"Blood"},{"key":"881_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.7326\/0003-4819-140-8-200404200-00005","volume":"140","author":"PD Stein","year":"2004","unstructured":"Stein PD, Hull RD, Patel KC et al (2004) D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 140:589\u2013602","journal-title":"Ann Intern Med"},{"key":"881_CR29","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolicevents in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232\u20131239","journal-title":"J Natl Cancer Inst"},{"key":"881_CR30","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902\u20134907","journal-title":"Blood"},{"key":"881_CR31","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","volume":"116","author":"C Ay","year":"2010","unstructured":"Ay C, Dunkler D, Marosi C et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116:5377\u20135382","journal-title":"Blood"},{"key":"881_CR32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1160\/TH12-04-0241","volume":"108","author":"J Thaler","year":"2012","unstructured":"Thaler J, Ay C, Pabinger I (2012) Venous thromboembolism in cancer patients-risk scores and recent randomised controlled trials. Thromb Haemost 108:1042\u20131048","journal-title":"Thromb Haemost"},{"key":"881_CR33","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. (2016) the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00881-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00881-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00881-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:42:10Z","timestamp":1678509730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00881-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00881-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"7 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}